Company
Quanta Therapeutics
Developing best-in-class allosteric inhibitors for RAS-driven cancers
Also known as Quanta Therapeutics, Inc.
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
- Headquarters
- South San Francisco, CA, United States
- Legal name
- Quanta Therapeutics, Inc.
Claim, correct or request removal
Record updated 28 September 2026
About
Quanta Therapeutics is a private biopharmaceutical company focused on the most prevalent and elusive target in oncology—RAS. Our vision is to develop novel small molecule cancer medicines by selectively targeting protein-protein interactions that are key to oncogenic RAS activity. Driving Quanta's success is our unique high-throughput platform that applies Second Harmonic Generation (SHG) optical technology to identify allosteric modulators of protein complexes.
Funding snapshot
- Total raised
- $146MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $76.2M2023-05-10
Funding rounds
- Round, 2023
- $76.2M2023-05-10, SEC form D sold, 17 investors
- Round, 2023
- $30M2023-02-09, SEC form D sold, 9 investors
- Round, 2021
- $40.2M2021-10-20, SEC form D sold, 10 investors
Products
- Other
- QTX3034
- Other
- QTX3544
Loading relationship preview